Notice of AGM

RNS Number : 6766I

SkinBioTherapeutics PLC

06 December 2022

 

SkinBioTherapeutics plc

Notice of Annual General Meeting

6 December 2022- SkinBioTherapeutics plc (AIM: SBTX or the "Company"), a life science company focused on skin health, announces that its Notice of the Annual General Meeting (AGM) has been issued to shareholders and is now available on the Company's website: www.skinbiotherapeutics.com .

The AGM will be held at 9:30am on Thursday 29 December 2022 at The Clarion Hotel, Witney Way, Boldon, NE35 9PE.

The Company's audited report and accounts for the year ended 30 June 2022, including all notes to the financial statements ("the Annual Report"), are expected to be published, and final results for the same period announced, by 23 December 2022. As a result, a General Meeting will be held in early 2023 to propose the Resolutions to receive and adopt the Annual Report and Accounts and to re-appoint the auditors, to allow for the Annual Report to be sent to shareholders the required time in advance of the General Meeting. The time, date and venue for the General Meeting will be announced in due course.

-Ends-

For more information please contact:

SkinBioTherapeutics plc Stuart J . Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com .

 

END

 

 

NOABKPBDBBDBOBK